Anzeige
Mehr »
Lynx Broker
Login
Mittwoch, 23.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12BHU ISIN: NL0010872420 Ticker-Symbol: A28 
Tradegate
23.10.19
17:34 Uhr
2,555 Euro
+0,035
+1,39 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AFFIMED NV Chart 1 Jahr
5-Tage-Chart
AFFIMED NV 5-Tage-Chart
RealtimeGeldBriefZeit
2,525
2,550
22:00
2,410
2,665
22:00

Aktuelle News zur AFFIMED Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.10.Affimed N.V.: Affimed Reports Progress on Key Clinical Development Programs17
28.08.Affimed N.V.: Affimed to Participate in Investor Conferences in September14
08.08.Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2019 Results - Earnings Call Transcript10
AFFIMED Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!
07.08.Affimed N.V. - 6-K, Report of foreign issuer3
07.08.Press Release: Affimed Reports Second Quarter 2019 Financial and Operational Results129Heidelberg, Germany, August 7, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today...
► Artikel lesen
01.08.Affimed: Put This Company On Your Watch List15
31.07.Affimed (AFMD) Presents At 2019 Wells Fargo Biotech Corporate Access Day - Slideshow4
31.07.Affimed N.V.: Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on ...9
01.07.Affimed now on Russell 2000, 3000 and Microcap Indexes7
01.07.Affimed N.V.: Affimed Added to the Russell 2000, 3000 and Microcap Indexes1
27.06.Affimed N.V. - 6-K, Report of foreign issuer3
24.06.New data on Affimed's lead candidate fails to excite investors, shares down 12%24
24.06.Minerva Neurosciences leads healthcare gainers; Avinger and Affimed among losers6
24.06.Press Release: Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 201970Heidelberg, Germany, June 24, 2019 -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today...
► Artikel lesen
12.06.Affimed N.V.: Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, ...13
04.06.Affimed N.V. - 6-K, Report of foreign issuer11
04.06.Affimed N.V.: Affimed Announces Annual General Meeting of Shareholders11
03.06.Affimed N.V.: Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen's ...12
29.05.Affimed N.V.: Affimed to Present at the Jefferies 2019 Healthcare Conference4
23.05.Affimed (AFMD) Earnings and Sales Exceed Estimates in Q112
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,1